Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda. by Hansen, Kristian Schultz et al.
RESEARCH ARTICLE
Cost-effectiveness analysis of introducing
malaria diagnostic testing in drug shops: A
cluster-randomised trial in Uganda
Kristian Schultz Hansen1,2*, Siaˆn E. Clarke3, Sham Lal3, Pascal Magnussen4, Anthony
K. Mbonye5,6
1 Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London,
United Kingdom, 2 Department of Public Health, Section for Health Services Research, University of
Copenhagen, Copenhagen, Denmark, 3 Department of Disease Control, London School of Hygiene and
Tropical Medicine, London, United Kingdom, 4 Centre for Medical Parasitology, University of Copenhagen,
Copenhagen, Denmark, 5 Directorate of Clinical and Community Services, Ministry of Health, Kampala,
Uganda, 6 School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda
* krha@sund.ku.dk
Abstract
Background
Private sector drug shops are an important source of malaria treatment in Africa, yet diagno-
sis without parasitological testing is common among these providers. Accurate rapid diag-
nostic tests for malaria (mRDTs) require limited training and present an opportunity to
increase access to correct diagnosis. The present study was a cost-effectiveness analysis
of the introduction of mRDTs in Ugandan drug shops.
Methods
Drug shop vendors were trained to perform and sell subsidised mRDTs and artemisinin-
based combination therapies (ACTs) in the intervention arm while vendors offered ACTs fol-
lowing presumptive diagnosis of malaria in the control arm. The effect on the proportion of
customers with fever ‘appropriately treated of malaria with ACT’ was captured during a ran-
domised trial in drug shops in Mukono District, Uganda. Health sector costs included: train-
ing of drug shop vendors, community sensitisation, supervision and provision of mRDTs
and ACTs to drug shops. Household costs of treatment-seeking were captured in a repre-
sentative sample of drug shop customers.
Findings
The introduction of mRDTs in drug shops was associated with a large improvement of diag-
nosis and treatment of malaria, resulting in low incremental costs for the health sector at US
$0.55 per patient appropriately treated of malaria. High expenditure on non-ACT drugs by
households contributed to higher incremental societal costs of US$3.83. Sensitivity analysis
showed that mRDTs would become less cost-effective compared to presumptive diagnosis
with increasing malaria prevalence and lower adherence to negative mRDT results.
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Conclusion
mRDTs in drug shops improved the targeting of ACTs to malaria patients and are likely to be
considered cost-effective compared to presumptive diagnosis, although the increased costs
borne by households when the test result is negative are a concern.
Introduction
The private health sector in Africa is an important supplier of treatment for malaria distribut-
ing more than half of all antimalarial drugs in many malaria-endemic countries [1,2]. Easy
access to antimalarial drugs must be weighed against the risk of substandard practices in a
sector often characterised by weak regulation and enforcement in low income countries. Arte-
misinin-based combination therapies (ACTs) recommended as the first-line treatment for
uncomplicated malaria [3] are the most effective but also the most expensive antimalarial on
the world market, and sales of cheaper antimalarial monotherapies continue to be common in
many countries [4–7]. The effectiveness of the treatment may be further diminished if less
than full courses are sold or inadequate instructions are given to patients on how to take the
drugs [8–11]. Furthermore, despite the WHO recommendation in 2010 for parasitological
confirmation prior to malaria treatment [3], the vast majority of private suppliers do not as yet
routinely offer malaria diagnostic testing before selling drugs. A presumptive diagnosis based
on clinical signs and symptoms alone will typically result in over-diagnosis of malaria, with
recent research showing that more than half of customers purchasing antimalarial drugs from
drug shops did not suffer from malaria [1,12,13].
Market interventions to improve malaria treatment in the private sector include the idea of
a global subsidy on quality assured ACTs at the factory level introduced as part of the Afford-
able Medicines Facility—malaria (AMFm) with the expectation that with low price and
increased affordability, ACTs would become more widely available in both the public and pri-
vate sectors, and simultaneously drive out low-priced and less effective antimalarial mono-
therapies [14]. Pilot evaluations in several countries found that the AMFm subsidy approach
achieved considerable success in fulfilling these expectations [15–17]. Subsidising parasitologi-
cal testing was not part of this initiative despite the possibility that without a test, low priced
ACTs might be prescribed to many fever patients not suffering from malaria. Rapid diagnostic
tests for malaria (mRDTs) are accurate, easy to use with a quick result, and require limited
training and may therefore increase access to parasitological diagnosis in both public and pri-
vate sectors [1,2,18,19]. There is currently limited experience with subsidising mRDTs in
Africa although one study found that introducing mRDTs in Ugandan drug shops increased
uptake of testing by customers [20].
The present study was a cost-effectiveness analysis of an intervention to improve the target-
ing accuracy of sales of subsidised ACTs in Ugandan drug shops by providing drug shop ven-
dor training in mRDT-based diagnosis and access to subsidised mRDTs, compared to drug
shops offering only clinical diagnosis and subsidised ACT treatment. At the commencement
of the current research, ACT treatment was not subsidised for the private health sector in
Uganda. Despite this, subsidised ACTs were introduced in this research both in the interven-
tion and comparator arm as Uganda was one of the AMFm pilot countries [17] and Ministry
of Health considered making ACT subsidisation permanent.
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Methods
Study area and population
A cluster-randomised trial was conducted in registered drug shops in Mukono District, Cen-
tral Uganda; an area with perennial malaria transmission and with a fever prevalence of 42%
among children below 5 years in 2011 [21]. The majority of the population live in rural areas
and are predominantly subsistence farmers. Registered drug shops are licensed to sell non-pre-
scription drugs, including antimalarial drugs but not antibiotics or injections. At the beginning
of the present study, parasitological diagnosis was not commonly available in drug shops,
although mRDTs or microscopy were available at government health facilities [5].
Intervention
The intervention consisted of training drug shop vendors to perform and sell subsidised
mRDTs and advise on the purchase of ACTs in accordance with national treatment guidelines,
and at low subsidised prices. Participating drug shops received these commodities for free, to
be sold at agreed recommended retail prices in 2011 of US$0.20 for an mRDT and US$0.40–
1.19 for a course of ACT depending on age, as informed by a prior willingness-to-pay study
[22]. Drug shops in the control arm also received ACTs for free and offered these to customers
at the same subsidised prices, but based on clinical diagnosis only. All drug shops in both arms
treated customers with signs of severe malaria with rectal artesunate without charge and subse-
quently recommended referral. Details of the training intervention and supporting activities
are available online (www.actconsortium.org/RDTdrugshops) and in prior publications
[23,24]. In brief, all drug shop vendors attended a 3-day participatory training workshop on
malaria case management, including training on the signs and symptoms of malaria and
administration of ACT or rectal artesunate (depending on severity), with drug shops in the
intervention arm receiving an additional day of training on how to perform and interpret
mRDT diagnostic tests. This was followed by close support supervision with site visits for the
first three months of implementation after which supervision was scaled down considerably.
Community sensitisation was also carried out to inform the population about the upcoming
study, the benefits of mRDT testing, and the availability of mRDTs from local health facilities
and trained drug shop vendors. In summary, pricing of commodities, training and supporting
activities were identical between the two study arms except that drug shops in the intervention
arm were allowed to sell subsidised mRDTs based on one additional day of training.
Measurement of effect
The primary aim of the trial was to evaluate the effect of mRDT diagnostic testing on the accu-
racy of targeting of ACTs. Antimalarial treatments sold by drug shop vendors were thus vali-
dated by expert microscopy on a blood slide collected by the vendor from the customer at the
time of consultation and read later by the research team (reference diagnosis). The measure of
effect was ‘appropriate treatment of malaria with ACT or rectal artesunate (depending on
severity of symptoms)’—a composite indicator defined as: a patient with a positive reference
diagnosis of malaria purchasing a course of ACT (or receiving rectal artesunate for free) or a
patient with a negative reference diagnosis not sold an ACT (or receiving rectal artesunate).
The proportion of patients appropriately treated of malaria with ACT or rectal artesunate
in each study arm was obtained from a cluster-randomised trial in Mukono District [24]. A
cluster was defined as a natural grouping of registered drug shops in close geographical prox-
imity. Twenty clusters were randomised either to diagnosis by mRDT or diagnosis by clinical
signs and symptoms, with 10 clusters in each arm. Informed consent to participate in the trial
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was obtained from drug shop vendors prior to training. For every customer seeking treatment
for fever, drug shop vendors recorded the diagnosis, mRDT result (intervention arm only),
and any ACT treatment sold in a register designed for this purpose. Vendors were not asked to
routinely record other drugs sold. Appropriate treatment of patients for malaria with ACT or
rectal artesunate was measured over a 12-month period from January-December 2011 where
7522 customers were recruited in the intervention arm and 5797 in the control arm [24].
(There were very few rectal artesunate treatments (<1%). For the remainder of the paper,
ACT or rectal artesunate depending on severity of symptoms are therefore simply referred to
as ‘ACT’).
Measurement of costs
Economic costs of resources were measured from both the public health sector and societal
perspectives and presented separately. All cost figures were adjusted to the 2011 price level
using an annual inflation rate of 8.8% corresponding to the average annual increase in the
GDP deflator in Uganda from 2004 to 2013 and presented in US dollars (UGX2523 = US$1)
[25].
The total costs of resources used for training of drug shop vendors, supervision, and com-
munity sensitisation were considered a health sector cost. Personnel costs of these three
activities were captured through interviews with participating staff who were asked to esti-
mate days utilised and about their gross monthly salary. All other costs were obtained from
project financial accounts that had been maintained throughout the study period. Training
of drug shop vendors, an initial period of close support supervision and community sensiti-
sation were expected to have a longer useful lifespan beyond the evaluation period of the
2011 calendar year and were treated as capital goods with annual equivalents calculated
assuming a lifespan of 5 years and a real discount rate of 3% [26]. As all mRDTs and courses
of ACT and rectal artesunate were supplied free to drug shops, the cost of acquiring these
was also considered a health sector cost. The mRDT utilised in this study, First Response,
was available in Uganda in 2011 at US$0.87 per test, including shipping and quality control.
Adding an assumed test wastage rate of 5%, as well as the costs of estimated consumption of
sterile gloves, cotton wool, and spirit, this resulted in a unit cost of US$1.00 per mRDT per-
formed. The median prices per course of ACT treatment with artemether-lumefantrine and
rectal artesunate suppository were obtained from an international drug price list [27]. A rec-
ommended ten percent was added for shipping [27] and another 12.5% added to cover stor-
age and quality control in-country (personal communication, Central Medical Stores).
Assuming 10% wastage, the estimated cost per course of ACT in 2011 ranged from US$0.77
for a child below 3 years of age to US$2.25 for an adult treatment dose and US$0.74 for a rec-
tal artesunate suppository.
Household costs were captured for a two-week period following the visit to a drug shop in a
random sample of 506 drug shop customers and interviewed at home 4 days after their visit to
the drug shop followed by a second home visit between days 10–14. Interviewers visited drug
shops participating in the cluster-randomised trial [24] according to a randomised schedule to
identify recent customers from the registers kept by drug shop vendors. Interviewers inquired
from the patient, or main caregiver in case of a child, all relevant out-of-pocket expenditure on
transport, drugs, consultation fees, diagnostic tests, special foods purchased to aid recovery,
incurred at the time of the initial visit to a drug shop, and as well as during any subsequent
treatment seeking visits to any health provider. Respondents were also asked about the number
of days they were unable to perform their normal activities due to illness. Lost time was valued
at US$1.21 per day corresponding to the GDP per capita per day in 2011 [25].
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The sample size for household cost interviews was calculated to test a hypothesis that out-
of-pocket expenditure would be lower in the intervention arm. To detect a decrease of at
least 30% in mean out-of-pocket expenditure in the intervention arm from a mean cost of
UGX3500 in the control arm as informed by previous, unpublished research in Mukono Dis-
trict, and assuming k = 0.25, power of 80%, a significance level of 5% in a trial with 10 clusters
per arm, required 250 interviews per arm [28].
Incremental cost-effectiveness analysis
A decision analysis approach [29,30] was used to link data on cost and effects from the differ-
ent primary data collection activities conducted in Mukono District described above. Accord-
ing to the decision tree utilised for the mRDT arm (Fig 1), a customer visiting a drug shop
offering parasitological diagnosis must first decide whether to purchase an mRDT or not fol-
lowed by a decision by customer and vendor to adhere to the test result and choose what drugs
to purchase. A simpler decision tree was used for the presumptive arm (Fig 2). All event proba-
bilities required for the decision tree in each arm were obtained from the trial [24] except the
probability of additional treatment-seeking following the drug shop visit which was captured
from the subsample of household cost interviews. Total health sector and societal costs by
study arm were calculated by populating the decision trees with unit cost estimates per drug
shop visit. The annualised 2011 costs of training of drug shop vendors, supervision, and com-
munity sensitisation by study arm were divided by the number of customer visits enrolled in
the trial during the 2011 calendar year arriving at the average unit cost per visit for these three
activities. Estimated costs per mRDTs and ACTs supplied to drug shops and borne by the
health sector included the prices of commodities themselves, transport, quality control and
other required supplies (see the previous section). Patients’ out-of-pocket expenditure on
mRDTs and ACT treatments purchased during drug shop visits were assumed to equal the
recommended retail price of these commodities in the trial period. Responses from the 506
household cost interviews suggested that this was a fair assumption. Household cost per visit
of other drugs, fees, food, transport, and time lost during the initial and subsequent visits were
obtained from the household interviews. All event probabilities and cost input used to popu-
late the decision trees for the cost-effectiveness analysis are listed in Table 1.
Total health sector and societal costs and number of patients appropriately treated of
malaria were calculated for a standard population of 1000 drug shop customers in each study
arm using the populated decision trees. The incremental cost-effectiveness ratio (ICER) was
estimated by dividing the difference in the total costs in the two arms by the difference in the
number of patients appropriately treated of malaria in the two arms. The ICER represented
the cost per additional drug shop customer appropriately treated of malaria if subsidised
mRDTs were introduced into drug shops that previously diagnosed malaria presumptively.
Sensitivity analyses
Univariate sensitivity analyses were performed to assess the robustness of the estimate of the
ICER of introducing mRDTs into drug shops to relevant parameters including malaria preva-
lence among drug shop customers, accuracy of the mRDT and adherence to test results. As
malaria prevalence and number of customers were both found to be higher in the mRDT arm
as compared to the presumptive arm in 2011 [24], a scenario analysis assuming the same level
(equal to the average) for these parameters in both arms was performed to assess the impact of
this imbalance.
Probabilistic sensitivity analysis (PSA) was developed to estimate the combined influence
of sampling uncertainty in relevant parameters [29] using beta distributions for the event
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PLOS ONE | https://doi.org/10.1371/journal.pone.0189758 December 15, 2017 5 / 18
probabilities in the decision trees and gamma distributions for all household cost parameters
(Table 1). Random and simultaneous selection of values from these parameter distributions,
followed by calculation of ICERs [31], was performed 10000 times in Excel (Microsoft,
Seattle). The resulting estimated uncertainty of the ICERs was summarised by plotting joint
Fig 1. Decision model for customers visiting drug shops offering mRDT diagnosis, Mukono District, Uganda. * According to expert
microscopy on a blood slide collected the by drug shop vendor from the customer at the time of consultation and read later by the research team
(reference diagnosis).
https://doi.org/10.1371/journal.pone.0189758.g001
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incremental costs and incremental effects from replacing presumptive diagnosis by mRDTs in
the cost-effectiveness plane and using these scatter plots to derive cost-effectiveness acceptabil-
ity curves (CEACs). These curves were derived by calculating the proportion of pairs of incre-
mental cost and effects and consequent ICERs where the introduction of mRDTs would be
considered cost-effective given different levels of willingness-to-pay (WTP) of the health policy
maker per appropriately treated patient for malaria [32–34].
Ethical statement
Ethical approval for the research was granted by review boards at the Uganda National Council
of Science and Technology and London School of Hygiene and Tropical Medicine. Written
informed consent was obtained from drug shop vendors to participate in the trial and from
the patient (or caregiver) prior to household interviews. Verbal consent was sought from
patients at the time of drug shop consultation for an mRDT and/or research blood slide.
Results
The main results of this research are presented in Table 2 for a standard population of 1000
customers in each of the two study arms. The introduction of mRDTs in the intervention
arm resulted in a significant increase in the number of fever patients appropriately treated of
malaria compared to the presumptive arm—751 versus 319 customers or an increase of 433
per 1000 febrile customers seen (95% CI 424 to 442). The ICER from a health sector perspec-
tive was US$0.55 (95% CI US$0.51 to US$0.60) meaning that introducing subsidised mRDT
diagnosis in drug shops currently offering presumptive treatment with subsidised ACT would
cost the health sector US$0.55 per additional patient appropriately treated of malaria. Applying
a broader societal perspective, which includes health sector and household costs, the incre-
mental cost of introducing mRDTs was US$3.83 per additional patient appropriately treated
of malaria (95% CI -US$23.87 to US$30.81).
The absolute health sector costs were similar in the two arms, at US$3.13 per drug shop cus-
tomer with suspected malaria seen in the mRDT arm and US$2.89 in the presumptive arm
(Table 2)–a difference of US$0.24 per customer. These were the average costs per customer
Fig 2. Decision tree for customers visiting drug shops offering presumptive diagnosis, Mukono District, Uganda.
* According to expert microscopy on a blood slide collected the by drug shop vendor from the customer at the time of consultation
and read later by the research team (reference diagnosis).
https://doi.org/10.1371/journal.pone.0189758.g002
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suspected of malaria for training, supporting interventions, and commodities (ACTs and diag-
nostics) by arm to be financed by the Ministry of Health. Health sector costs constituted 33%
and 37% of total societal costs in the mRDT and presumptive arms respectively. The most
important health sector cost component was ACTs consumed forming 10% and 21% of total
societal cost in the two arms and mRDTs utilised which constituted 11% in the mRDT arm.
The sum of absolute cost of mRDTs and ACTs was higher in the mRDT arm than in the pre-
sumptive arm meaning that the extra cost of supplying mRDTs was only partially offset by a
reduction in the consumption of ACTs.
Societal cost was considerably higher at US$9.42 and US$7.76 per customer with suspected
malaria in the mRDT and presumptive arms respectively (Table 2)–a difference of US$1.66
Table 1. Parameters utilised in decision model and distributions for probabilistic sensitivity analyses (PSA), incremental cost-effectiveness analy-
sis of replacing presumptive diagnosis by rapid diagnostic tests in drug shops in Mukono District, Uganda, 2011 (US$1 = UGX2523).
Model parameter - - - - - - - - - - Value - - - - - - - - - - Source Distribution in PSA
mRDT arm Presumptive arm
Malaria positivity rate among customers suspected of malaria (%) # 43.49 31.76 [24] Point estimate
Share of customers suspected of malaria purchasing mRDT (%) 99.95 NA [24] Beta
Sensitivity of diagnosis (%) 91.75 99.89 [24] Beta
Specificity of diagnosis (%) 62.92 0.20 [24] Beta
Adherence to positive mRDT result (%) 99.10 NA [24] Beta
Adherence to negative mRDT result (%) 98.60 NA [24] Beta
Community sensitisation, cost per visit (US$) 0.12 0.15 * Point estimate
Training of drug shop vendors, cost per visit (US$) 0.57 0.61 * Point estimate
Supervision, cost per visit (US$) 0.47 0.48 * Point estimate
Cost per mRDT, paid by the health sector (US$) 1.00 NA § Point estimate
Cost per ACT course (< 3 years) paid by the health sector (US$) 0.77 0.77 § Point estimate
Cost per ACT course (3–7 years) paid by the health sector (US$) 1.63 1.63 § Point estimate
Cost per ACT course (8–14 years) paid by the health sector (US$) 1.98 1.98 § Point estimate
Cost per ACT course (> 14 years) paid by the health sector (US$) 2.25 2.25 § Point estimate
Cost per rectal artesunate paid by the health sector (US$) 0.74 0.74 § Point estimate
Price per mRDT in drug shops (US$) 0.20 NA & Point estimate
Price per ACT course (< 3 years) in drug shops (US$) 0.40 0.40 & Point estimate
Price per ACT course (3–7 years) in drug shops (US$) 0.59 0.59 & Point estimate
Price per ACT course (8–14 years) in drug shops (US$) 0.59 0.59 & Point estimate
Price per ACT course (> 14 years) in drug shops (US$) 1.19 1.19 & Point estimate
Price per rectal artesunate in drug shops (US$) 0.00 0.00 & Point estimate
Out-of-pocket expenditure for non-ACT drugs per visit (US$) 2.08 1.10 € Gamma
Out-of-pocket expenditure for fees, transport, etc per visit (US$) 0.58 0.56 € Gamma
Probability of additional treatment-seeking (%) 9.82 10.22 € Beta
Out-of-pocket expenditure per additional visit (US$) 2.58 1.84 € Gamma
Time utilised for travelling and waiting per fever episode (days) 0.10 0.10 € Gamma
Time unable to perform normal activities per fever episode (days) 2.11 1.80 € Gamma
Value of lost time per day (US$) 1.21 1.21 [25] Point estimate
# According to expert microscopy on a blood slide collected by the drug shop vendor at the time of consultation and blind reading later by the research team
(reference diagnosis).
* According to study accounting system (see text).
§ Including price of commodity, transport, disposables and waste (see text).
& Recommended retail price agreed with drug shop vendors participating in the trial.
€ Sample of household cost interviews (see text).
https://doi.org/10.1371/journal.pone.0189758.t001
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per customer. Household costs formed 67% and 63% of total societal costs in the mRDT and
presumptive arms respectively. Out-of-pocket expenditure on drugs other than ACTs (such as
antipyretics, various injections, antibiotics, and cough syrups) formed an important part of
household cost, and non-ACT drug expenditure was twice as high among customers visiting
mRDT drug shops as compared to customers visiting drug shops offering presumptive diagno-
sis. Only ten percent of households in the sample reported seeking additional care after the
first visit to a drug shop and similar in both arms (9.8% versus 10.2%) indicating that diagnos-
tic testing in drug shops did not have a marked effect on subsequent treatment seeking behav-
iour (Table 1). Household costs related to additional health care seeking formed only 2% of
total societal cost in both arms. Opportunity costs of lost time were also similar constituting
close to one third of total societal cost in both study arms. Days lost due to illness or caring for
an ill family member were the most important component of opportunity costs of lost time.
The univariate sensitivity analyses suggested that the ICER of introducing mRDTs from
both the health sector and societal perspectives was robust except when selected parameters
Table 2. Costs and effects in a standard population of 1000 individuals suspected of malaria by study arm and incremental cost-effectiveness
ratio (ICER) of replacing presumptive diagnosis by rapid diagnostic tests in drug shops in Mukono District, Uganda, 2011 (US$1 = UGX2523).
- - - mRDT
arm -- -
- - Presumptive arm - -
N % N %
Individuals suspected of malaria 1000 100 1000 100
True malaria # 435 43 318 32
Purchased ACT 609 61 998 100
Appropriately treated * 751 75 319 32
US$ % US$ %
Health sector cost per 1000 individuals 3129 33 2890 37
Community sensitisation 116 1 148 2
Training of vendors 572 6 608 8
Supervision of vendors 470 5 482 6
mRDTs 999 11 0 0
ACTs 973 10 1651 21
Household cost per 1000 individuals 6287 67 4868 63
mRDTs (first visit) 198 2 0 0
ACTs (first visit) 435 5 734 9
Other drugs (first visit) 2164 23 1101 14
Fees, travel, food (first visit) 581 6 562 7
Drugs, fees, travel, food (subsequent visits) 254 3 188 2
Opportunity cost of time lost 2655 28 2283 29
Total societal cost per 1000 individuals 9415 100 7757 100
Incremental analysis (Replace presumptive diagnosis by mRDT in 1000 individuals suspected of malaria)
Incremental number of appropriately treated [95% CI] 433 [424; 442]
Incremental health sector cost, US$ [95% CI] 239 [224; 254]
Incremental societal cost, US$ [95% CI] 1658 [-10350; 13254]
ICER health sector perspective, US$ [95% CI] 0.55 [0.51; 0.60]
ICER societal perspective, US$ [95% CI] 3.83 [-23.87; 30.81]
# According to expert microscopy on a blood slide collected by the drug shop vendor at the time of consultation and blind reading later by the research team
(reference diagnosis).
* Individual with a positive reference diagnosis of malaria purchasing a course of ACT or an individual with a negative reference diagnosis not purchasing an
ACT.
https://doi.org/10.1371/journal.pone.0189758.t002
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were markedly different from their central values (Table 3). If the malaria prevalence among
drug shop customers had been 60% instead of 43% and 32% as found in the mRDT and pre-
sumptive arms, then the ICER from a health sector perspective increased from US$0.55 to
US$1.92. At malaria prevalence levels of below 16% the ICER was negative meaning that the
mRDT had lower health sector cost and higher effect than presumptive diagnosis. A lower
mRDT price, increased mRDT specificity, and higher popularity of drug shops offering
mRDTs would improve the cost-effectiveness of mRDT introduction while decreased adher-
ence to mRDT results and lower ACT prices decreased cost-effectiveness. All other parameters
and assumptions incorporated in the univariate sensitivity analysis did not have strong influ-
ence on the ICER levels.
In the scenario analysis, assuming identical malaria prevalence and number of clients in
2011 with suspected malaria in mRDT and presumptive diagnosis drug shops, the ICER
increased to US$1.33 from a health sector perspective and to US$5.42 from a societal
Table 3. Sensitivity to selected parameters of the incremental cost-effectiveness ratio (ICER) of replacing presumptive diagnosis by rapid diag-
nostic tests in drug shops in Mukono District, Uganda, 2011 (US$1 = UGX2523).
Parameter & - - - ICER in US$ - - - Parameter & - - - ICER in US$ - - -
Health sector Societal Health sector Societal
Malaria prevalence among customers (43% and 32%) Prob. of subs. treatment in mRDT arm (9.8%)
10% -0.09 2.72 2% 0.55 3.34
20% 0.08 3.21 20% 0.55 4.47
40% 0.61 4.82 35% 0.55 5.40
60% 1.92 8.72 Prob. of subs. treatment in presumptive arm (10.2%)
80% 9.72 32.03 2% 0.55 4.20
Sensitivity of mRDT (92%) 20% 0.55 3.39
70% 0.28 4.61 35% 0.55 2.71
85% 0.48 4.04 ACT price
100% 0.63 3.61 30% decrease 1.02 4.30
Specificity of mRDT (63%) 40% decrease 1.18 4.46
50% 0.98 4.75 50% decrease 1.34 4.61
70% 0.37 3.44 mRDT price (US$0.70)
90% 0.00 2.63 30% decrease -0.08 3.20
100% -0.14 2.33 40% decrease -0.29 2.99
Adherence to negative mRDT (99%) 50% decrease -0.50 2.78
40% 2.49 7.61 Discount rate (3%)
60% 1.56 5.81 1% 0.56 3.84
80% 0.96 4.63 7% 0.54 3.82
Change in number of customers in mRDT arm 10% 0.53 3.81
40% lower 2.21 5.49 Com. sens., training and intense sup. (every 5 years)
40% higher -0.16 3.12 Every 3 years 0.49 3.77
80% higher -0.55 2.73 Every 7 years 0.58 3.86
100% higher -0.69 2.59 Opportunity cost per day (US$1.2)
Change in number of customers in presumptive arm US$0.4 0.55 3.26
40% lower -1.23 2.05 US$0.8 0.55 3.54
40% higher 1.32 4.60 US$1.6 0.55 4.11
80% higher 1.74 5.02 US$2.0 0.55 4.39
100% higher 1.89 5.17 US$2.5 0.55 4.75
& Actual parameter value observed in the trial [24] is shown in parenthesis.
https://doi.org/10.1371/journal.pone.0189758.t003
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perspective (S1 Table). This increase was due to a larger difference in health sector cost
between the study arms and a smaller difference in the number of patients appropriately
treated of malaria compared to the central estimates utilised in Table 2.
The probabilistic sensitivity analysis (PSA) from a health sector perspective found that all
iterations led to positive incremental health sector costs and a positive incremental number of
individuals appropriately treated of malaria in the cost-effectiveness plane (Fig 3a). Shifting
from presumptive to mRDT diagnosis therefore resulted in a significant increase in the
Fig 3. Probabilistic sensitivity analysis (health sector perspective). (a) scatter plot of incremental health
sector cost in US$ and incremental number of individuals appropriately treated of malaria resulting from
replacing clinical diagnosis of malaria by rapid diagnostic test in drug shops, Mukono District, Uganda, 2011
(US$1 = GHS1.51) and (b) cost-effectiveness acceptability curve.
https://doi.org/10.1371/journal.pone.0189758.g003
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number of appropriately treated individuals with a mean of 433 (95% CI 424 to 442) out of
1000 drug shop customers and a significant increase in health sector cost with mean US$239
per 1000 (95% CI US$224 to US$254). Using this scatterplot to develop the CEAC by calculat-
ing the share of the pairs of incremental costs and effects leading to ICERs below given thresh-
old values (Fig 3b), it was found that if a policy maker was willing to pay (WTP) at least US
$0.55 per patient appropriately treated of malaria, the probability of mRDT introduction being
a cost-effective intervention was 46%. This probability increased markedly to 79% and 100%
if WTP was US$0.57 and US$0.61 or above. There was therefore a high probability that the
introduction of mRDTs would be cost-effective even at very low WTP.
The PSA from a societal perspective revealed a higher degree of uncertainty associated with
making a decision with respect to the introduction of mRDTs. The scatterplot of joint incre-
mental societal cost and incremental number of individuals appropriately treated of malaria in
the cost-effectiveness plane (Fig 4a) exhibited considerable variation in costs being sometimes
positive and sometimes negative with a mean of US$1658 per 1000 customers (95% CI –US
$10350 to US$13254). The CEAC revealed that much higher WTP was required to deem the
introduction of mRDTs as a cost-effective intervention. If the WTP was US$1, the probability
of mRDT introduction being cost-effective was 38%; increasing to 56%, 74%, and 92% if the
WTP was US$5, US$10, and US$20 respectively (Fig 4b).
Discussion
The present study compares the cost and effects of introducing subsidised mRDT-based diag-
nosis versus presumptive diagnosis in private drug shops in Uganda selling subsidised ACTs.
This design is appropriate for a situation where subsidised ACTs have already been introduced
and where a decision must now be made if it would be cost-effective also to introduce subsi-
dised mRDTs in private drug shops. From a health sector perspective, the introduction of
mRDTs in drug shops is likely to be considered a highly cost-effective intervention since the
cost to the health sector per extra appropriately treated client of malaria was low at only US
$0.55. For comparison, this was substantially lower than the range of health sector cost of US
$5.0 to US$10.5 per appropriately treated patient of introducing mRDTs in public health cen-
tres recently found in different African countries [35–37]. The main explanations for the very
low ICER of introducing subsidised mRDTs in drug shops were the substantial improvement
in the appropriate targeting of subsidised ACT treatment to customers infected with malaria
parasites (43% points) and the fact that the comparator, presumptive treatment with subsi-
dised ACTs, involved similar levels of training, supervision and community sensitisation and
therefore costs as the mRDT intervention. Although mRDT use in drug shops did not result in
a net cost saving for the government, they helped to ensure that subsidised ACTs were more
accurately targeted at minimal additional cost (US$0.24 per customer suspected of malaria).
The sensitivity analyses performed did not give reason to change this conclusion except at
high malaria prevalence among customers, low adherence to negative mRDTs, and lower ACT
price where the introduction of mRDTs would be increasingly less cost-effective relative to
presumptive diagnosis.
From a wider societal perspective, it was found that the total societal cost of introducing
mRDTs was considerably higher and estimated at US$3.83 per additional appropriately treated
patient due to the high proportion of costs borne by households. The variation in household
costs as captured during household interviews was large and right-skewed with the standard
deviation being at a similar level or higher than the mean cost of all household cost categories.
This is however not an uncommon pattern in cost data [29,38]. Consequently, the decision
to introduce mRDTs is also more uncertain from a societal perspective as the probability of
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mRDTs being a cost-effective intervention only exceeds 75% if a high value (more than US
$10) is attached to each additional customer appropriately treated of malaria. From a narrow
health sector perspective, mRDTs would be deemed cost-effective with a probability of 75% at
much lower WTP of US$0.57.
Our results underline the large share of societal cost that was borne by households seeking
treatment in the private sector, even when subsidised ACTs were available, and important
explanations were extensive purchasing of non-ACT drugs as well as the opportunity cost of
Fig 4. Probabilistic sensitivity analysis (societal perspective). (a) scatter plot of incremental societal cost
in US$ and incremental number of individuals appropriately treated of malaria resulting from replacing clinical
diagnosis of malaria by rapid diagnostic test in drug shops, Mukono District, Uganda, 2011 (US$1 = GHS1.51)
and (b) cost-effectiveness acceptability curve.
https://doi.org/10.1371/journal.pone.0189758.g004
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lost time. Non-ACT drug expenditure was almost twice as high among customers who visited
drug shops with mRDT diagnosis compared to customers attending drug shops with clinical
diagnosis and total out-of-pocket expenditure on drugs was thus 41% higher among customers
attending drug shops that offered mRDT-based diagnosis. Another important explanation of
high household cost was opportunity cost of lost time where patients were unable to do their
normal activities. Valuing lost time per day by the GDP per capita might be an overestimate
for a population consisting predominantly of subsistence farmers but assuming a lower value
of lost time did not have a strong influence on the ICER level.
A key parameter to judging the introduction of mRDTs a cost-effective intervention or not
was adherence to negative mRDT results. The trial found a very high adherence to negative
mRDT results by customers and vendors [24]. Diagnostic testing appeared to enhance the rep-
utation of drug shops and may have increased custom [39], potentially increasing the desire of
vendors to comply with the intervention. Another contributing factor to this high adherence
could be that negative mRDTs did not just represent a loss in drug shop vendor income due to
lower antimalarial drug sales but also an opportunity to sell a range of other drugs. In this set-
ting, there appeared not to be a strong financial incentive to disregard negative mRDT results
on the part of the vendors.
The availability of mRDTs in drug shops led to a significant decrease in ACT treatment
sold to patients with no malaria parasites in their blood from almost 100% in the presump-
tive arm to 37% in the mRDT arm. National roll-out of mRDTs in the private retail sector
may therefore contribute to delayed emergence and spread of artemisinin resistance. If such
longer term positive effects had been included in the analysis, this would have improved the
cost-effectiveness of mRDTs relative to presumptive diagnosis. In addition, mRDTs ensured
that many more customers with non-malarial fever were correctly informed that they did
not have malaria (close to 0% in the presumptive arm and 63% in the mRDT arm). Such
knowledge may improve the chances that these non-malarial febrile illnesses are correctly
treated as patients may start searching for an alternative, correct diagnosis and treatment.
Although this aspect was not formally investigated as part of this research project, improved
detection and treatment of non-malarial febrile illnesses would make mRDT introduction
more cost-effective.
This research also pointed to some risks related to the introduction of mRDTs in drug
shops. Among the malaria parasite-free patients as judged by expert microscopy, 37% of these
were deemed positive by mRDT and almost all of these patients purchased an ACT. Some of
these patients may not be treated for other causes of fever as both DSV and patient may regard
ACT as sufficient treatment for the fever. Similarly, as Mukono District is an area with peren-
nial malaria transmission, some mRDT positive patients may be asymptomatic carriers of
malaria with other co-infections and again may not be treated immediately for the other causes
of fever, thus increasing the risk of adverse health for patients.
The shift in pattern of medicines purchased in favour of non-ACT drugs among customers
visiting drug shops offering mRDT may be appropriate given the higher percentage of patients
correctly diagnosed as not suffering from malaria. However, there may also be an increased
risk that following a negative mRDT, DSVs diagnose and treat conditions they are not prop-
erly trained for again potentially elevating the risk to patients.
There were no reported deaths among the sample of 506 customers interviewed in their
homes and only 3% of the customers visiting an mRDT drug shop answered during the inter-
view that they were still ill on day 14. Nevertheless, additional research would be desirable to
investigate the extent of the risks identified above as an input into the decision whether and
how mRDTs should be introduced into the private retail sector.
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Limitations
Household costs of non-ACT drugs were captured through the interviews with customers.
There may be several sources of error associated with self-reported household costs during
interviews including recall bias with respect to types and prices of drugs purchased. In addi-
tion, it was only possible to perform a limited number of home interviews. As a result, the
household costs for non-ACT drugs may have been determined with higher uncertainty than
the household costs of ACT.
The trial was performed in registered drug shops, and there were other sources of malaria
treatment within the study area including public facilities and private clinics, as well as unreg-
istered drug shops. Thus although we cannot rule out the possibility of differential treatment-
seeking by customers according to the method of diagnosis available in different drug shops,
which may account for the differing prevalence of infection between the two study arms, we
consider this difference to reflect a realistic situation of provider choice. Thus, although we
also present results from a scenario analysis assuming equal prevalence and attendance in
drug shops by diagnostic method for comparison, we would contend that the central estimates
are a more realistic and thus generalisable assessment of the cost-effectiveness of introducing
mRDTs into private drug shops.
Ministry of Health staff were closely involved in the design of the intervention to ensure
that the training and supervision approach used in the trial would be feasible to replicate at
scale. Nevertheless, the effects of the intervention were estimated under relatively controlled
conditions, and comparable effects and cost-effectiveness could prove harder to achieve under
routine operational conditions.
The focus of this research was the ‘appropriate treatment of malaria with ACT’. The appro-
priateness of treatment of customers not having malaria could not be investigated as this
would have required an independent clinical assessment of the patient, which was beyond the
scope of this trial. It was therefore not possible to judge if the household expenditure on non-
ACT drugs were well spent in terms of having a positive medical benefit. The analysis exam-
ined only the immediate costs and effects of the intervention, and did not consider potential
longer-time economic benefits that could arise, such as improved detection and treatment of
other non-malaria febrile illnesses, and delayed emergence and spread of drug resistance due
to reduced drug pressure.
Conclusions
The present research suggests that the introduction of subsidised mRDTs in private drug
shops in Uganda is desirable from a pure cost-effectiveness perspective compared to a situation
with presumptive diagnosis. It was found that the availability of this parasitological test in drug
shops significantly increased the proportion of patients appropriately treated of malaria (from
32% to 75%) at a low incremental cost of US$0.55 per appropriately treated patient from a
health sector perspective and US$3.83 from a societal perspective. Furthermore, the additional
cost per suspected malaria patient being offered subsidised mRDT and ACT was only US$0.24
to be covered by the health sector and US$1.66 for the society as a whole compared to custom-
ers purchasing presumptive diagnosis and subsidised ACT. The increased costs borne by
households when the test result is negative are a potential concern, and additional research
would be helpful to investigate if the medicines purchased by patients diagnosed not to suffer
from malaria are appropriate, have sufficient clinical benefit and represent good value for
money.
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